There was a reduction in volume of involvement, cardiac pyrophosphate activity, native T1, and extracellular volume during a median of 369 days between scans in patients with ATTR-CM being treated.

Patients diagnosed with wild-type ATTR-CM on or before 65 years of age had better survival after diagnosis compared to patients who were diagnosed after 65 years. Wild-type transthyretin-mediated ...

A multidisciplinary approach is necessary for the deep phenotyping and proper clinical management of individuals with primary mitochondrial diseases. A large percentage of patients (60%) with primary ...

Patients with ATTR‐CM who experienced an early improvement in left ventricular ejection fraction following cardiac resynchronization therapy implantation had a longer survival. New research shows that ...

Patients with ATTR-CM had significantly impaired global longitudinal strain and higher mechanical dispersion compared to their first-degree relatives who were not affected by the disease. Increased ...

The treatment could potentially help patients reduce the use of glucocorticoids and immunosuppressants, the authors of the study said. The safety and efficacy of efgartigimod for the treatment of ...

The ODDS score showed strong predictive accuracy for 1-year transplant-free survival across varying levels of disease severity and oxygen needs. Researchers have devised a novel composite score that ...